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Summary 
The  BDC  2.5  T  cell  clone  is  specific  for  pancreatic  ]3-cell  antigen  presented  by  I_Ag7, and 
greatly  accelerates  diabetes  when  injected  into  10-21-d-old  nonobese  diabetic  (NOD)  mice. 
The BDC  2.5  T  cell receptor  (TCI<)  has been solubilized  as a  TCR.-IgG1  chimeric protein. 
All  NOD  mice  immunized  against  BDC  2.5  TCR-IgG1  produced  antibodies  recognizing 
TCP, C~x/C]3 epitopes that were inaccessible on the T  cell surface. 56% of the mice produced 
antibodies  against the BDC  2.5  clonotype  that specifically blocked antigen activation  of BDC 
2.5  cells.  We have  used the  adoptive  transfer model  of diabetes  to  demonstrate  that maternal 
immunization with soluble  TCR  protects young mice from diabetes induced by the BDC 2.5 
T  cell clone. 
A 
s a result of the  somatic  recombination  of TCR  gene 
segments  in  developing  T  cells,  each  TCIL  contains 
some structural epitopes that are unique to a particular T  cell 
clone and some that are shared among different clones  (1). 
Immunity  against  a  TCR  could  therefore  regulate  the 
function of either a specific T  cell clone or a set of clones in 
vivo,  depending  on  the  nature  of the  epitope  recognized. 
In the rat and mouse models  of experimental  autoimmune 
encephalomyelitis  (EAE) l,  oligoclonal  suppression  of au- 
toreactive  T  cells  appeared  to  occur  after  immunization 
with peptides derived from the ix- or [3-chains of the TCIL 
of encephalitogenic  T  cells.  Immunization  of Lewis  rats 
with synthetic peptides based on the V13-8.2 CDtL2  (2) or 
V~-D[3-JI3  (3)  sequences  of the  TCP,.  of rat  encephalito- 
gemc T  cells suppressed the induction  of EAE.  immuniza- 
tion of B10.PL  or  (SJL  ×  B10.PL)  F i mice with a pepude 
derived  from  framework  region  3  of  the  TCFL  V[3-8.2 
chain protected both strains against EAE  (4,  5).  Similar im- 
munizations  of DBA/2 or (PLJ  ×  SJL)  F 1 mice with a V[3- 
8.2  CDR2  peptide  appeared  to induce  clonal  anergy in all 
V[3-8.2 + T  cells (6). The mechanism of regulation by TCIL 
1Abbreviations used m thts paper, dc, dual chain; EAE, experimental autoam- 
mune encephalomyelitis; HRP, horseradish peroxtdase; MOI, multlphc- 
ity of refection; NOD, nonobese diabetic; sc, single chain; SS-, cell sur- 
face staining negative; SS +, cell surface staining poslnve. 
peptide immumzation is thought to involve primed CD4 + 
(5)  or CD8 +  (6)  T  cells that recognize  the peptide  in asso- 
ciation  with  MHC  molecules  on  the  surface  of either  an 
APC  or  the  autoreactive  T  cell  itself (7).  Although  there 
are experimental data suggesting that T  cells primed against 
the TCR  V[3-8.2  CDR2  peptide can inhibit the activation 
of myelin basic protein--specific encephalitogenic rat T  cells 
in  vitro  (8),  the  details  and  immunosuppressive  effects  of 
the mechanism are uncertain.  T  cells have yet to be shown 
to  process  their  own  TC1L  and  present  MHC-associated 
epitopes.  Likewise,  it  is  not  known  whether  professional 
APC present TCR epitopes derived from autoimmune T  cells 
in the course of disease. Furthermore, in rat EAE, immuni- 
zatlon  with  the  V~-8.2  CDIL2  peptide  sometimes  in- 
creased  the  seventy  of disease  and converted  the  normally 
acute, self-limiting disease into a chronic disorder (9). 
An alternative approach to immunotherapy is to perform 
TCIt. immunizations  designed to induce  antibodies against 
TCI< variable region epitopes  expressed on the T  cell sur- 
face.  The  ability of injections  of V[3-8.1/.2  family-specific 
mAb to prevent EAE in mice (10) suggests the feasibility of 
this approach.  Although it has been shown that immuniza- 
tion with peptides  representing TCI< V[3-8.2  CDR2  (11), 
conserved VDJ, and consensus JR sequences  (3) could stim- 
ulate  the  production  of antibodies  recognizing  cell-surface 
TCtL,  V[3-8.2  CDR2  peptide  immunization  was  not  al- 
ways  successful  in  stimulating  such  a  response  in  rats  (9). 
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TCP,. V13-6 stimulated antibody responses against the pep- 
tides but not the intact TCR  (12). To investigate immuno- 
regulation  resulting  from  an  antibody  response  against 
TC1L  epitopes,  a  more  reliable  immunogen  is  required. 
Fortunately,  newly  developed  techniques  for  the  produc- 
tion of soluble TCR  (13--16)  now allow immunization with 
proteins  containing the extracellular domains  of the TCR. 
Such  immunization  should  stxmulate  the  immune  system 
with  an  array  of different  T  cell  epitopes,  some  of which 
are likely to resemble those of native cell-surface TCR. 
The BDC 2.5 T  cell clone is l-AgV-restricted and specific 
for pancreatic islet [3-cell antigen  (17,  18).  In vivo, it accel- 
erates  the  onset  of  &abetes  when  injected  into  young 
nonobese  diabetic  (NOD)  mice  (19).  We  have  produced 
soluble recombinant BDC 2.5 TCR  by constructing a chi- 
meric protein composed of the extracellular domains of the 
TCR  chains  (Vot-1/Cot,  and  V[3-4/C[3)  linked  to  the 
hinge,  CH2  and  CH3  domains  of the  mouse  IgG1  heavy 
chain.  The technique is similar to that used for the produc- 
tion  of a  y/8  TCR  in  transiently  transfected  COS  cells 
(20);  but  we  have  used  a  baculovirus  expression  system 
shown previously to allow the successful production of sol- 
uble 0t/j3  TCP, from the D0-11.10  T  cell hybridoma  (21), 
and the N15  cytotoxic T  lymphocyte clone (22). 
The  studies reported here characterize  the immunologi- 
cal specificity of the  antibody response  to BDC  2.5  TCP,.- 
IgG1  protein  in NOD  mice.  Unlike  rat  and  mouse  EAE, 
diabetes in the NOD  mouse does not involve obviously re- 
stricted TCR  Voe or V[3  gene segment usage  (23),  and it is 
extremely  unlikely  that  immunization  with  a  single  TCP,. 
would  affect  the  natural  progression  of disease.  We  have 
therefore investigated the ability of antibodies raised against 
BDC 2.5 TCR-IgG1  to protect against the adoptive trans- 
fer of diabetes by the BDC 2.5 T  cell clone in young'NOD 
mice.  Because  the  recipient  NOD  mice  are  injected  with 
BDC  2.5  cells  between  10  and  21  d  of age,  they  are  too 
immature  to  be  actively  immunized.  We  have  overcome 
this  difficulty by immunizing female NOD  mice and mat- 
ing them. Their offspring have been investigated for the ef- 
fect  of maternally  transferred  anti-TCR  antibodies  on  the 
diabetogenic activity of injected BDC  9.2.5 T  cells. 
Materials and Methods 
Mice.  NOD mice were purchased from Taconic Farms (Ger- 
mantown, NY), NOD/LtRIP-Tag transgenic mice (24) from the 
Ammal Resources Unit of The Jackson Laboratory (Bar Harbor, 
ME), and AKR/J mice from The Jackson Laboratory. The RIP- 
Tag  transgene  is  a  recombinant  simian  virus  40  oncogene  in 
whmh the rat insulin 5'  promoter has been inserted immediately 
upstream of the simian virus 40 early region (25),  Transgene ex- 
pression is restricted to the [B-cell and results in the formation of 
[B-cell tumors  in  the  pancreas  in  vivo.  Offspring  of crosses  be- 
tween NOD/Lt RIP-Tag and normal NOD mice were weaned 
and prowded with 5% (wt/vol) sucrose-supplemented water, and 
sugar cubes. From 10 wk of age, blood glucose levels were closely 
momtored,  and  when  the  mice  became  severely hypoglycemic 
(blood glucose concentration --<50 mg/dl) they were killed for is- 
let cell preparation. 
T Cell Lines.  The  pancreatic  [3-cell-specific,  l-AgT-restricted, 
NOD mouse T cell clones, BDC 2.5 and 6.9, were propagated as 
previously described (17,  18) with the mochfication that x-irradi- 
ated (5,000 rids) Met cells isolated from NOD/LtlKIP-Tag  mice 
were substituted for conventional NOD  mouse Mets as a source 
of antigen. Before antigen-specific prohferanon assays, BDC  2.5 
and BDC 6.9 cells were rested for at least 14 d after the last stim- 
ulation with antigen and spleen cells.  The T  cell responses were 
assayed  in  U-bottomed  96-well  plate  cultures.  Each  well  con- 
tamed 2  X  104  cloned  T  cell  and  5  X  10 s x-irradiated  (3,000 
rads)  NOD  spleen  cells  as  a  source  of APC  in  200  ~1  Eagle's 
Hank's  atmno  acid  medium  (Irvine  Scmntific,  Santa  Ana,  CA) 
supplemented with 5% FCS (Hyclone Laboratones, Logan, UT), 
2 mM glutamme,  100 U/ml penicillin,  100 U/ml streptomycin, 
and 5  X  10 -s M  2-ME. Cultures were set up with and without 
7.5  X  103 x-irra&ated  (5,000 rids)  Met cells  as a source of ant> 
gen, incubated at 37°C m 5% CO2 for 96 h, and pulsed with 1 IxCi 
[3H]thymidme (6.7 C1/mmol; ICN, Irvlne, CA) for the final 16 h 
of incubation. The cultures were harvested, and isotope incorpo- 
ration measured by scintillation  counting.  The  mean counts  per 
minute were calculated from triphcate cultures. 
The  lsolation and in vitro propagation  of the  I-At-restricted, 
hen  egg conalbumm peptide-speclfiC AKIL  mouse T  cell clone, 
D10  (TCIL  Vo~-2/V[3-8.2),  has been  descnbed previously  (26). 
The B1  T  cell line was derived from the spleen of an ummmu- 
nlzed NOD mouse. The B1 cells appear to be specific for an un- 
identified autoantlgen of NOD spleen cells. Although no cloning 
procedure was used,  100% of the cells express TC1K V[~-8.1/2 as 
determined  by  m~munofluorescent  stainmg.  The  B1  line  was 
propagated in vitro similarly to the D10 line, except that x-Irradi- 
ated NOD spleen cells were used as a source of antigen. The I-E k- 
resmcted, pigeon cytochrome C peptide-specific mouse T cell clone, 
B10  (TC1K Va-11/V[3-16),  was  kindly  provided  by  Dr.  S.M. 
Hedrick  (Department  of Biology,  Umversity  of California,  San 
Diego); it was propagated m vitro as described previously (27). 
Cloning of TCR and IgG1  Genes.  Total  RNA  was  prepared 
from ~5  X  10  ~ cells (28) and 1.0 }xg converted to single-stranded 
cDNA  using  superscript  reverse  transcriptase  (GIBCO/BRL, 
GaIthersburg,  MD)  according  to  the  manufacturer's  protocol. 
TCR  and  [gG1  genes were  amplified from  5%  of each  cDNA 
preparation in 75-txl reactions containing:  10 mM Tns-HC1, pH 
8.3,  50 mM KC1,  0.001%  (wt/vol)  gelatin,  1.5 n'~Vl MgCI2, 200 
mM  dNTPs,  2.5  U  AmpliTaq  DNA polymerase  (Perkin Elmer 
Corp.,  Branchburg,  NJ),  and  270  nM  of each  primer.  Primers 
were designed using published gene sequences encoding the TCR 
V[3-4,  Vow-l, CoL  and  CI3  segments,  and  the  IgG1  heavy chain 
constant-regmn  (23,  29,  30).  The  primer pairs  for the BDC 2.5 
TCR [B-chain cDNA were: MusVi3-4, 5'-CCTCTAGAAGAT- 
CTCCATGGGCTCCATTTTCCTCAGTT-3';  and  5'D1013, 
5'-GGAATTCAGATCTCCGTCTAGTCGTGATGAACCA- 
CGAGGTACCAGATCAG-3'.  The  primer pa,rs  for  the  BDC 
2.5  or-chain  cDNA  were:  MusV0t-1,  5'CCTCTAGAAGAT- 
CTGCATGCATTCCTTACATGTTTCACTA-3  '; and 5 'D 100t, 
5'-GGAATTCAGATCTGATGGAGCAGTCGTTGATCCA- 
CGTGGTACCAGGTC-3'  The  primer  pairs  for  the  IgG1 
hinge, CH2  and CH3  cDNA were: 5'-IgG1,  5'-GCTGGTAC- 
CCAGGGGTAGTGGTTGTAAGCcTTGcATATGTAcAGT- 
CCCAGAAGA-3';  and 3'-IgGl,  5'GAAGATCTcATTTACCA- 
GGAGAGTGGGAGAGGCTCTTCTC-3'  Cycling  parameters 
were 95°C for 30s,  62°C for 30s,  and 72°C for 60s for 30 cycles. 
PCtK products were  ctoned into  the vector pC1KII  (Invitrogen, 
1756  Maternal Immunization with Soluble TCR in NOD Mice San Daego,  CA)  to  yield the  plasmids  pCIL-BDC25o~,  pC1L- 
BDC2513,  and pC1L-IgG1.  The  cloned genes  were  completely 
sequenced using Sequenase  (United States Biochermcals,  Cleve- 
land, OH) and the manufacturer's protocol. They were found to 
be adentical to published sequences  (23, 31). 
Construction of Baculovirus Transfer Vectors.  Standard  techniques 
were  used for construction of recombinant DNA  (32). p5/598 
and p7/598 (Fig. 1 B) were constructed by hgating into either the 
BamHI or BglII sites of the polyhedrin/Pl0 'double-promoter' 
plasmid, pAcUW51 (Pharmingen, San Diego, CA), both a BglII- 
KpnI,  BDC  2.5  TCtL  [3-chain  cDNA  fragment  from  pCR- 
BDC2513, and a KpnI-BglII, IgGl cDNA fragment from pC1L- 
IgG1. Next, the BDC 2.5 TCR-IgG1 baculovirus transfer-vector 
p20/599 (Fag. 1 B) was made by hgating between the EcoRI and 
KpnI sites of p5/598 an EcolLI-BamHI fragment encoding the 
BDC 2.5  TCR [3/IgG1  chimeric chain from p7/598,  and two 
fragments  from  pCP,-BDC25ci;  a  BgllI-PvulI fragment and  a 
PvulI-KpnI  fragment, which together encode the BDC 2.5 TCR 
or-chain. 
Two  "single-promoter"  recombinant  transfer  vectors  with 
genes  encoding BDC 2.5  TCP, sangle or- and [3-chains as IgG1 
chimeras downstream of the polyhedrln promoter were also con- 
structed,  p7/599 was constructed by hgating into the BamHI site 
of pVL941  both a BgllI-KpnI BDC  2.5  TClL c~-chain cDNA 
fragment from pCR-BDC25c~,  and the  Kpnl-BgllI IgG1  frag- 
ment for pCR-IgG1. Similarly, p3/598 was constructed by hgat- 
ing into the BamH1 sate ofpVL941(PharMingen) both the BgllI- 
KpnI, BDC 2.5 TC1L [3-chain cDNA and the KpnI-BgllI, IgG1 
cDNA fragments. 
Similar procedures were used to construct baculovirus transfer 
vectors encoding D10 TCR-IgG1 and D10 TCR-IgG1 proteins. 
The  vectors  encoding D10  dual  chain  (dc) TCR  (oL/[3-het- 
erodimer), and the D10 TCP, individual o~- and [3-chains wall be 
described  elsewhere  (Khandekar,  S.S., P.P. Brauer, J.W. Naylor, 
H.-C.  Chang,  P.  Kern, J.R.  Newcomb,  K.P.  LeClair,  H.S. 
Stump, B.M.  Bettencourt, E.  Kawasaki, J.  Baneroi, A.T. Profy, 
and B. Jones, manuscript submitted for pubhcation). 
Production  of Soluble TCR in Insect  Cells.  Sf9 cells were co- 
transfected with the recombinant transfer plasmid and linearized 
BaculoGold viral  DNA according to  the  manufacturer's (Phar- 
Mmgen) recommendations. Standard  procedures (33) were used 
to generate and amphfy clonal isolates of recombinant varus. Re- 
combinant viruses have been named after the transfer plasmid us- 
ing v as the prefix. 
To produce TCR-IgG1 protein for purificataon,  Sf9 or High 
5 (Invitrogen) cells were grown at 27°C in 6-8 1 spinner cultures 
an  serum-free  SF900II  medium  (GIBCO/BRL)  supplemented 
with 10 U/ml penicallln, 100 ~zg/ml streptomycin, and 0.25 ~g/ 
ml amphotericin B (Sigma Chemical Co., St. Louis, MO). When 
the  cell  concentration reached  0.8-1.2  ×  106/ml  the  cultures 
were infected with recombinant baculovirus at a multiplicity of 
infection (MOI) of 5 and incubated for a further 3 d.  Superna- 
tants  were  harvested  by centnfugation and filtration through  a 
I).2-~m filter. 
To compare the expression  levels of soluble TCR during re- 
fection wath different  recombinant baculovlrnses,  small-scale in- 
fecnons were  performed.  Duplicate or triplicate  60-mm &shes 
were seeded  wath 2  ×  106 Sf9  cells an trichoplusla  hi medium 
Fred Hank medium (JRH Sciences, Lenexa,  KS). After the cells 
had attached  (15-60 min) they were infected at a MOI of 5 with 
recombinant baculovirns. After 3 d the culture supernatants  were 
harvested. 
Recombinant  Proteins.  The producnon of D10 scTCR in Es- 
&erichia  coli will be  described  elsewhere  (Khandekar,  S.S., P.P. 
Brauer, J.W. Naylor, J.R. Newcomb, B.M. Bettencourt, J. Ban- 
erji, A.T. Pro@, and B. Jones, manuscript in preparation).  Bacu- 
lovirus-derived, immunoaffinity-purified  soluble CD4 was kindly 
donated  by  Dr.  Mane-Rose  van  Schravenchjk  (Procept  Inc., 
Cambridge, MA). 
Antibodies and Reagents.  Hybridomas producing the C[3-spe- 
cific  H57-597  mAb (34) and the  TCR Co~-specific H28  mAb 
(35) were  kindly provided by Dr.  Ellis Relnherz (Dana-Farber 
Cancer Instatute, Boston, MA). FITC-conjugated, or biotinylated 
anti-C[3  H57, anti-V[3-8.1/8.2, anti-V[3-6,  anta-Vot-2, and anti- 
V',/-3 mAb were purchased from Pharmmgen. FITC-conjugated 
anti-V[3-4 mAb was purchased  from Harlan Bioproducts for Sci- 
ence  (Indianapohs,  IN), and FITC-conjugated goat  anti-mouse 
Ig from Organon Teknlka, Durham, NC. Alkaline phosphatase- 
conjugated  streptavidin  was  purchased  from  Kaerkegaard  and 
Perry Laboratories,  Gaithersburg,  MD, and alkaline phosphatase- 
conjugated goat  antibodies specafic for mouse Ig K- and R-light 
chains  from  Southern Baotechnology Associates Inc., Birming- 
ham, AL. 
The hybndoma producing the TCR C[3-specific mAb, 501.1.1, 
was  derived from the  spleen of a  NOD  mouse that  had  been 
primed and boosted with soluble BDC  2.5  TC1L-IgG1  as  de- 
scribed  below.  4  d  after  the  final  l.p.  injecnon of antigen, the 
spleen  cells  were  fused  with  P3X63-Ag8.653  myeloma  cells 
(American Type Culture Collection, Rockville, MD) using stan- 
dard procedures (36). 
The D10 T  cell clone-specific  mAb 3D3 (26) was purified by 
protein A affimty chromatography. 
Immunoqffinity  Chromatography.  30  mg  of mAb  H57  were 
covalently coupled to 15 ml of protein A beads (Rephgen, Cam- 
bridge,  MA)  using  dimethylplmehmidate as  described  (37). 
Baculovirus-infected insect  cell  supernatants  were  concentrated 
approximately fivefold using a concentrator with a 10-kD mem- 
brane filter (Pellicon; Millipore, Bedford,  MA), filtered through a 
0.2-~m filter,  and passed over a H57-protem A column at 4°C 
wath a flow rate of 1-2 ml/rnln. The column was washed with 10 
column-volumes  of PBS and eluted wath 50 mM catrate, pH 3.0. 
Eluted fractions  were  neutralized with  1 M  Tris-HC1, pH  8.8, 
and  dialyzed  against  PBS.  Protein  concentrations were  deter- 
mined by the Bradford method (38), using BSA as a standard. 
Using samilar procedures,  mAb 3D3-proteln A columns were 
prepared and used to purify the soluble D10 TCR preparations: 
D10 dcTCR, D10 scTCR, and D10 TCR-IgG1 (Khandekar et 
al.,  manuscript submitted for publicanon), mAb H28  and H57 
columns were used to purify soluble D10 TCR ci- and [3-chain 
protems. 
hnmunoprecipitations,  SDS-PAGE  Analysis,  and  Immunoblotting. 
BDC  2.5  TCR-IgG1  was  precipatated  by standard  procedures 
(39) using an overnight 4°C incubanon with 10 ~tl anti-CoL H28 
or anta-C[3 H57 mAb covalently coupled protean  A beads. 4  × 
107-6  ×  107 T  cells were lysed in TBS contalmng 0.2% NP-40 
(Sigma  Chemical  Co.)  and protease  inhabitors  (1  mM  PMSF, 
NoL-p-tosyl-c-lysine chloromethyl ketone, EGTA, and EDTA; 2 
~zM leupeptln and pepstatin; 0.6 TIU/ml aprotanan; Sigma) at 107 
cells/ml for 45 min on ice. Lysates were clarified by centrifuga- 
tion and each  lysate was incubated wath  100  txl of H57  mAb- 
coupled protean A beads for 4 h. Subsequent steps in the analyses 
of both BDC 2.5 TCR-IgG1 and T cell-derived TCR were sim- 
ilar. The beads were extensively washed with TBS containing ei- 
ther 0.5% Triton X-100 for recombinant TCR or 0.05% NP-40 
for T cell-derived material, and the TCR proteins eluted by boil- 
ing an SDS  sample  buffer (2.3% SDS,  10%  glycerol,  62.5  mM 
1757  McKeever et al. Tris-HC1,  pH  6.8)  for 3  man,  with  or without  5% 2-ME.  The 
eluted proteins were fractionated by 10.5% or 12.5% SDS-PAGE 
(40).  Protein  bands  were  stained  with  Coomassie brilliant blue. 
For  Western  blotting,  proteins  were  separated  by  nonreducing 
SDS-PAGE,  transferred  directly  to  Immobllon-P  membrane 
(Milhpore),  and  probed  with  antisera  or mAbs  diluted  in  PBS. 
Annbody  reactivity was  detected  with  either  polyspeclfiC  goat 
ann-mouse  Ig  antibody  conjugated  to  horseradish  peroxidase 
(HRP)  (Cappel Laboratories, Durham, NC) or goat anti-hamster 
IgG-HRP (Cappel) at a  1:2,000 dilution. Western blots were vi- 
sualized using the enhanced chemiluminescence technique (ECL; 
Amersham  Corp.,  Arlington Heights,  IL).  In  some  experiments 
the  membranes  were  stripped  and  reprobed  according  to  the 
manufacturer's recommendations. 
Analysis of BDC 2.5 TCR-IgG1 by BIAcore.  The  binding  of 
TC1K Ca-specific H28 mAb and C~-speclfiC H57 mAb to BDC 
2.5 TCR-IgG1  protein was analyzed using the BIAcore biosen- 
sor (Pharmacia LKB Blotechnology Inc., Plscataway, NJ). 0.6 Ixg 
of immunoaffinity-punfied BDC2.5  TCR-IgG1  was coupled to 
dextran surface by standard amine chennstry (41).  A blank control 
surface was activated and blocked in the absence of soluble TCR. 
Affinity-purified H57  and  H28  mAb  (each  at  3  IxM)  were  in- 
jected over a control surface or over the BDC 2.5 TCR-IgG1- 
coupled surface.  The  mAb were  dialyzed against  and  diluted in 
Hepes-buffered saline  (10  mM Hepes,  150  mM NaC1,  3.4 mM 
EDTA, 0.005%  surfactant  P20,  pH 7.4).  Samples of 20 IM were 
injected at a flow rate of 5  IM/min and this flow rate was main- 
tamed throughout the experiment. Where necessary, the bmsen- 
sor surface was regenerated with 10 mM HC1. All binding exper- 
iments were conducted at 25°C.  The surface plasmon resonance 
signal was  recorded as resonance  units  versus time and  the data 
plotted as a "sensorgram." 
Immunofluorescence Staining and Flow Cytometry.  106  T  cells were 
incubated  for  30  min  on  ice  with  FITC-labeled  antibodies  or 
NOD  mouse nonimmune  serum or antiserum  diluted in  10  ~*1 
PBS supplemented with 5% fetal bovine serum and 0.1% sodmm 
azxde.  The  cells were washed three times.  After the antiserum 
incubation,  the  cells were  incubated  for a  further  30  mln  on 
ice  with  FITC-labeled  goat  anti-mouse  Ig  antibody  and  again 
washed.  In  experiments  designed  to  investigate  the  ability  of 
NOD antiserum to block the binding of TC1L-speclfic antibodies 
the cells were preincubated with antiserum m excess,  washed three 
times, and stained with FITC-labeled anti-V[3-4 and anti-C[3 mAb. 
The stained cells were fixed in 1% (wt/vol) paraformaldehyde in 
0.85%  saline,  and  analyzed  on  a  FACScan  ® (Becton Dickinson 
and Co., San Jose, CA) equipped with LYSYS II software. 
ELISA.  The  amounts  of soluble  heterodimeric  BDC  2.5 
TCR-IgG1  produced in the baculovlrus expression system were 
estimated by a direct sandwich ELISA. 96-well plates (MaxiSorp; 
Nunc, Naperville, IL) were coated overnight with 4 btg/ml TCR 
C[3-specific H57 mAb at 4°C, and blocked with  1% BSA in bo- 
rate-buffered saline for 2  h  at room temperature.  100-pA  samples 
of soluble TCR  diluted in borate-buffered saline with  1% BSA 
were added overnight at 4°C.  The plates were then washed and 
biotin-conJugated TCR  Cot-specific H28  rnAb  (1:500  dilunon) 
was added to each well. After 4 h incubation at room temperature 
the plates were washed and  developed with phosphatase-labeled 
streptavidin  (Kirkegaard and Perry Labs,  Gaithersburg,  MD)  and 
104  substrate  (Sigma  Chemical  Co.).  The  OD  at  405  nm  was 
measured  and  the  amounts  of soluble  heterodimeric  BDC  2.5 
TCR-IgG1  were estimated by comparison of OD values with a 
standard  curve  obtained  with  a  reference  preparation  of H57 
mAb affimty-purlfied BDC TCR-IgG1 protein. 
For  the  analysis  of serum  antibodies  from  mice  immunized 
with  soluble  recombinant  TCR,  96-well plates  were  incubated 
overnight at 4°C with soluble TCR  preparations at a concentra- 
tion  of 4  ~zg/ml  in  borate-saline  buffer,  pH  8.5.  Plates  were 
washed and blocked by standard procedures (42).  The solid phase 
was incubated  overnight at 4°C with  NOD  nonimmune  serum 
or antiserum,  or TCR-speclfic mAb, followed by an incubation 
with alkaline phosphatase-conjugated antibodies specific for mouse 
Ig K- and  h-hght  chains.  When  TCR  ot-cham,  V13-8,  and  Vot- 
specifc  biotlnylated  mAb  were  used  in  the  first  step,  alkahne 
phosphatase  conjugated streptavidin was used instead of the anti- 
light chain antibodies. The binding of antibodies was measured as 
absorbance  at  405  nm after reaction  of the  immune  complexes 
with 104 phosphatase substrate  (Sigma Chemical Co.). 
Immunizations.  NOD mice of 6-8 wk of age were primed by 
the subcutaneous injection into each hind limb of'~50 Ixl of a 1:1 
(vol/vol) emulsion of PBS and CFA (Sigma Chemical Co.) con- 
taining 200-300 Ixg/ml of recombinant TCIK protein. Where in- 
dicated, mice were boosted at least 14 d after priming, by the i.p. 
or i.v.  Injection  of 20  Ixg  of recombinant  protein  in  PBS  into 
each animal. Mice were bled from the retroorbital sinus 4 d after 
the last boosting injection, and the sera were heat inacnvated by 
incubation at 56°C for 30 min. 
Pancreatic Islet Isolation, and T Cell Purification.  Islet cells were 
isolated from (NOD/Lt RIP-Tag  X  NOD)  F 1  mouse  pancreata 
as previously described  (43),  but with the modification that  im- 
mediately after death the pancreas was infused with a collagenase 
(Boehringer Mannhmm)  solution  (4.0  mg/ml)  via the  common 
bile duct. The pancreas was excised, incubated in vitro for 15 mm 
at 37°C, and the encapsulated tumors dissected from exocrlne tis- 
sue and forced through  a  70-~m nylon mesh  (cell strainer;  Fal- 
con, Oxnard,  CA) to produce a single cell suspension. 
Normal mouse  T  cells were purified from spleen cells using 
T  cell enrichment columns (R & D  Systems, Minneapolis, MN) 
according to the manufacturer's instrucnons. 
Adoptive  Transfer of Diabetes by BDC 2.5 and BDC 6.9  T  Cell 
Clones.  The procedure was essentially that described previously 
(19).  NOD  mice between 10 and 21  d of age were injected with 
5  ×  106  to  10  ×  10 ~'T cells inavolume  of 0.5  ml. A  total of 
three rejections spaced at weekly mtervals was administered. Uri- 
nary sugar was momtored using test tape (Eli Lilly and Co., Indi- 
anapolis, IN) and the onset of diabetes was confirmed by measur- 
ing  blood  sugar  levels  with  a  Glucose  Analyzer  2  (Beckman 
Instruments Inc., Palo Alto, CA). A blood sugar concentration of 
>10  mM  indicated  diabetes.  Experiments  were  termmated  as 
soon as diabetes was diagnosed or by 4 wk after the first injecnon 
ofT cells. 
Results 
Characterization  of Soluble  TCR-IgG1  Chimeric  Receptors. 
A  schematic  diagram  of the  TCR-IgG1  chimeric  protein 
encoded by the recombinant baculovlrus is shown in Fig. 
1 A. TCR  derived from the NOD  mouse BDC  2.5  (TCR 
VcI-1/V[3-4)  T  cell clone (18,  23)  was expressed as a  solu- 
ble TCR-IgG1  chimeric protein.  Supematants  from Sf9 or 
High 5  cells infected with v20/599  (BDC 2.5 TCR-IgG1) 
recombinant  baculovirus  were  fractionated  by  immunoaf- 
finity chromatography  on  a  TCP,-C[3~specific,  H57  mAb 
column.  The bound  and  eluted BDC  2.5  receptor protein 
was  analyzed by SDS-PAGE  (Fig.  2  A).  Under  nonreduc- 
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Figure  1.  The  soluble BDC 
2.5  chimeric protein  and  the 
baculovirus  transfer vector  en- 
coding it.  (A)  Schematic of the 
BDC  2.5  TCR-IgG1  chlmenc 
molecule. (B)  Schematics show- 
ing the onentatlon of the TCP,. 
and  lgG1 coding  regions, and 
the polyhedrm and p 10 promot- 
ers in the p20/599  transfer vec- 
tor  for  the  expression of BDC 
2.5 TCR-IgG1. p5/598 and p7/ 
598 were intermediate constructs 
used in making the transfer vec- 
tors.  The  construction  of  the 
vectors is  described In Matenals 
and Methods. 
ing  conditions,  the  purified  receptor  migrated  as  a  major 
species  of  110  kD,  with  a  smaller  amount  of material  at 
~200  kD.  After  reduction,  the  protein  showed  a  band  at 
50-55  kD,  indicating  that  both  nonreduced  species  were 
formed by the disulfide linkage of50-55-kD  subunits.  The 
predicted molecular masses of the BDC 2.5 TCR  ot-chain- 
IgG1  and  ~-chain-IgG1  polypeptides  are  50,355  D  and 
55,319  D.  The apparent molecular masses of 50--55  kD for 
the  polypeptides  are  consistent  with  these  values.  Some 
variation  in  molecular  mass  of the  recombinant  protein  is 
to  be  expected  due  to  the  variable  high  mannose-type 
N-hnked glycosylation which is known to  modify recom- 
binant  proteins  synthesized  in  baculovirus-infected  insect 
cells  (44-46).  The  data  are  also  consistent  with  the  major 
nonreduced  110-kD  species being a  dimer of a  50-55-kD 
subunit. The minor amounts of nonreduced species of higher 
molecular mass presumably represent  oligomers formed by 
atypical  disulfide  bond  formation.  The  pre'sence  of TCR 
ot-  and  ~-chains  in  the  immunoamnity  purified  TCP,.- 
igG1  protein  was  investigated  by  immunoprecipitation 
with  Cot-specific  H28  mAb,  and  C[3-specific  H57  mAb. 
Each antibody precipitated approximately equal amounts of 
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Figure  2.  Ana]ysls of  NOD 
mouse  soluble  TCR-IgG1  chi- 
meric  proteins  by  SDS-PAGE. 
BDC  2.5  TCR-IgG1  protein 
was  purified by  lmmunoaffimty 
chromatography  on  an  antl-C[~ 
H57 mAb column. (A) BDC 2 5 
TCP,,-IgG1  protein was analyzed 
by  12.5%  SDS-PAGE  under 
nonreduclng (NR) and reducing 
(R) conditions  (/3) 20 Ixl of im- 
munoaffinlty-punfied BDC  2.5 
TCR-IgG1 at a concentration of 
0.75  mg/nd  were  precipitated 
with protein A-Sepharose beads 
coupled with H28  (anti-Ctx)  or 
H57  (anu-CI3)  mAb. The mate- 
rial  eluted  from  the  beads  was 
analyzed  by  12.5%  SDS-PAGE 
under reducing conditions as de- 
scribed  m  Materials  and  Meth- 
ods  The  lanes  are  labeled  with 
the  protein  A-Sepharose-cou- 
pled mAb used in the precipita- 
tion step. In (A) and (B) the pro- 
tein  bands  were  stained  with 
Coomassie  brilliant blue. 
material which  upon  reduction yielded the 50-55-kD  spe- 
cies  (Fig.  2  B).  The  immunoprecipitations  with H28-  and 
H57-coupled  beads  were  performed  quantitatively.  20-1xl 
samples  of H57-immunoaffinity  purified  BDC  2.5  TCR- 
IgG1  at  a  protein  concentration  of 0.75  mg/ml  were  pre- 
cipitated with  10 Ixl Sepharose beads that had been coupled 
with H28  or H57  mAb  at a  ratio  of 2  Ixg mAb/ml  beads. 
Consequently,  the  approximately  equal  intensity  of  the 
H28-  and  H57-immunoprecipitated  bands  observed  by 
SDS-PAGE  (Fig.  2  B) indicated that the H57-immunoaf- 
finity-purified material was mostly heterodimeric,  although 
the  presence  of some  aberrantly paired  ot/ot  and  J3/~3  ho- 
modimers could not be ruled out.  The heterodimeric nature 
of the  H57-immunoaffinity  purified BDC  2.5  TCR-IgG1 
was  also  indicated  by  the  use  of the  BIAcore  biosensor. 
Surface  immobilized  BDC  2.5  TCR-IgG1  bound  both 
H57 and H28 mAb  (Fig. 3).  In this experiment the binding 
was  confirmed  by  reversing  the  order  of injection  of the 
mAb  after regeneration of the surface with  10 mM  HC1.  A 
control  surface  without  immobilized  TCR  bound  neither 
mAb  (data not shown). 
A  direct  sandwich  ELISA  similar  to  that  described  by 
Chang  and colleagues  (22) was developed for estimation of 
3000  HCI 
ta  1000 
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Figure 3.  BIAcore blosensor measurement of the binding of H28 and 
H57 mAb to lmmoblbzed BDC  2.5 TCR-IgG1.  Affinity-purified  H57 
and H28 nkAb were sequentially injected at a concentration of 3 I~M over 
a surface coupled with 0.6 lag immunoaffinity-purlfied BDC 2.5  TC1K- 
IgGl  protein  The flow rate was 5 lal/mln. At the end of each bmdmg 
cycle, the blosensor surface was regenerated with 10 mM HCI. 
the yield  of BDC  2.5  TCR-IgG1.  Soluble  TCR  prepara- 
tions or baculovirus culture supernatants were incubated on 
plates coated with C[3-specific mAb  H57,  and the captured 
TC1K was detected with biotinylated Cot-specific mAb  H28 
and phosphatase-labeled streptavidin. A  standard curve was 
generated by the titration of a standard preparation of puri- 
fied  BDC  2.5  TCR-IgG1.  Only  heterodimenc  soluble 
TC1K  should be  detected  by the ELISA.  This was  verified 
by the demonstration that no binding material was found in 
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Figure  4.  Esnmatlon of amounts  of heterodlmerlc BDC  2.5  TCR- 
IgGI by ELISA. Sf9 cells were infected with recombinant baculovlrus at a 
MOI  of 5  5<  107/plate.  Infecnons were with v7/599  (BDC 2 5 TCR 
ct-IgGl) alone,  v3/598 (BDC 2.5  TCR  ~-IgG1) alone,  or mixtures of 
the two.  After  incubation for 3  d,  supernatants were harvested and the 
BDC  2 5  TCR-IgG1  assayed by ELISA  as  described in  Materials  and 
Methods. The ratios of the MOI ofv7/599 to v3/598 used to infect the 
cells are shown on the abscissa. 
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Figure 5.  NOD mice immu- 
nized with the BDC 2.5 TCP,- 
IgG1 protein  produce  antibod- 
ies  specific  for  the  BDC  2 5 
cell-surface TCP,. (A) T cells of 
the in&cated type were  stained 
by indirect lmmunofluorescence 
with  (1) nonlrnmune  NOD  se- 
rum  (line) or (2)  anu-BDC  2 5 
TCR-IgG1  antiserum (lon~ bro- 
ken line) followed by FITC goat 
anti-mouse  Ig  antibody.  TCP, 
expression was demonstrated by 
&rect immunofluorescent stain- 
mg  with  (3)  FITC  antl-VI34 
mAb  (short broken line) for BDC 
2.5  and  6 9 cells, and (5) FITC 
ann-TCR  C[3  mAb for punfied 
NOD  splemc T  cells (long-short 
broken line). (4)  Isotype-matched 
controls  were  FITC-ann-V[36 
for the  V134-speclfiC mAb, and 
FITC  ann-V~/3 for  the  TCR 
C~-speclfiC  n-LAb (dotted line). (13) 
BDC 2.5 cells were prelncubated 
(30  mln  on  me  In  presence  of 
0  I%  sodmm  azlde)  with  (6) 
buffer alone (line), (7) a 1'10 &- 
lutlon  of pooled  NOD  mouse 
nonimmune serum (long broken  line),  or (8) a  1:10 dilution  of NOD  mouse antl-BDC 2.5 TCR-IgG1  antiserum (short broken  line).  The cells were then 
stained with FITC antl-V~4 mAb, or FITC ann-TCR  C[~  as indicated. 
the supernatants of Sf9 cultures infected with either the v7/ 
599  or  the  v3/598  recombinant  baculovirus  containing 
gene constructs encoding only the BDC 2.5 TCR  oL-IgG1 
or ~-IgG1 chains (Fig. 4), whereas the supernatants of cul- 
tures  simultaneously infected  with  both  v7/599  and  v3/ 
598  contained heterodimeric material at a level of 500 ng/ 
ml when the ratios of the v7/599:v3!598 MOI were 10:10 
and  10:5.  The ELISA could therefore be used with confi- 
dence  to  routinely monitor the amounts  of heterodimeric 
BDC  2.5  TCR-IgG1  protein purified from  the  superna- 
tants  of large  scale  Sf9  and  High  5  spinner  cultures  in- 
fected with the "double-promoter" recombinant baculovi- 
rus v20/599 encoding both the chimeric TCP,. cx-IgG1 and 
[3-IgG1 constructs. In five batches, varying in volume from 
3 to 7 liters, 0.5-1 mg/liter was routinely obtained after H57- 
lmmunoaffinity  purification.  This  represented  an  overall 
yield of 12.5-25% since the unfractionated culture superna- 
rants appeared to  contain °°4  mg/liter as estimated by the 
ELISA. 
Tile  Antibody  Response  to  the  BDC  2.5  TCR-IgG1  Chi- 
meric Protein.  NOD  mice were primed with the BDC 2.5 
TCP,:IgG1  protein  in  CFA.  Boosting  injections without 
adjuvant were given 14-21 d after priming and repeated aSer 
a  further  14  d.  All antisera collected 4  d  after the  second 
boosting were found to contain antibodies recognizing the 
soluble BDC 2.5 TCR-IgG1 protein by the ELISA, whereas 
indirect immunofluorescence revealed that 18 out of the 32 
animals immunized made antibodies that bound the surface 
of the BDC  2.5  T  cell clone (TCR:  Ve~-I/V[3-4). Each  of 
these  18  antisera appeared to be specific for the BDC  2.5 
clone because BDC  6.9 cells (TCR.: V~x-13.1/VI3-4) were 
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not stained. The antisera reacting only in the ELISA were 
pooled,  and  the  pool  will be  referred  to  as  cell surface- 
staining negative (SS-). The 18 antisera that both reacted in 
the ELISA and stained the BDC 2.5 cells were also pooled 
to produce a cell surface-staining positive pool (SS+). 
Analysis of the  SS  +  pool  indicated  that  the  antibodies 
produced in response to BDC  2.5  TCI:L-IgG1 immuniza- 
tion and which recognized the BDC  2.5  cell surface were 
clonotype specific. The  data are shown  in  Fig.  5  A.  The 
antiserum pool stained BDC  2.5  T  cells but not BDC  6.9 
T  cells or normal splenic NOD  T  cells, suggesting that the 
antibodies recognized clonotypic epitopes of the BDC  2.5 
TCR.  Detailed mapping of these  epitopes in  the  variable 
region of the BDC  2.5  TCP,. was  not possible due to the 
lack of mAb specific for this receptor; however, some asso- 
ciation with the V~-4 segment was indicated by the initial 
observation that individual mouse antisera could inhibit the 
binding of V[3-4 family-specific, FITC-labeled mAb to the 
BDC 2.5 cell surface. Data obtained with the SS + pool are 
shown in Fig. 5  B. BDC 2.5 cells were incubated with an- 
tiserum,  nonimmunized  NOD  mouse  serum,  or  buffer, 
washed,  and  stained  with  anti-VI3-4  or  anti-C~  FITC- 
mAb. Pretreatment with the anti-BDC 2.5 TCR-IgG1  an- 
tiserum reproducibly inhibited staining with the anti-V[3-4 
mAb  in  comparison  with  pretreatment  with  nonimmune 
serum. As expected, given the apparent clonotype specific- 
ity of the antiserum (Fig. 5 A), it did not interfere with the 
binding of the  Cl3-specific, H57  n-LAb any  more  strongly 
than nommmune serum. 
Antibodies  recognizing  TCI<  clonotypic  epitopes  are 
usually able to inhibit the antigen-specific responses of the 1/20 Anu- D10 TCR AS  • 
1/100 AntI-BDC 2.5 TCR-IgGI  AS  1 
1/20 Antt-BDC 2 5 TCR-IgGI  AS  1 
No afltlSerum II 
No antigen con~ol 
0 
BDC 2.5 T Cell Response 
Mean cprn 
BDC 6.9 T Cell Response  Figure  6.  NOD mouse ann- 
BDC 2.5 TCR-IgG1 antiserum 
specifically blocks the  antigen- 
speofic response of the BDC 2.5 
T  cell clone in  wtro. Rested 
BDC  2.5  or  6.9  T  cells were 
premcubated (37°C for 1 h) with 
or  without  the  Indicated dilu- 
uons  of anusera raised against 
BDC  2.5  TCR-IgG1  or  DI0 
dcTCR proteins, and then tested 
for their response to NOD/RIP- 
Tag islet cells and NOD APC m 
the  standard prohferauon assay. 
The anu-D10 dcTCR anuserum 
used as a control was raised m 
AKR mice, and contained anubodles specific for cell-surface clonotypic epltopes of the D10 T cell clone. Unstlmulated control cultures received APC 
without islet cells. The values represent the mean [3H]thymldme  incorporated during a 16-h pulse after a 72-h culture period. 
appropriate  T  cell  clone  in  vitro  (47).  Likewise,  the  SS + 
antiserum  strongly  inhibited  the  in  vitro  proliferative  re- 
sponse of the BDC 2.5  cells  to antigen,  but had no effect 
on the response of the BDC 6.9 cell (Fig. 6). The responses 
of both  the  BDC  2.5  and  BDC  6.9  T  cell  clones  were 
stimulated  by  irradiated  NOD  mouse  spleen  cells  as  a 
source of APC, and NOD/LtRIP-Tag pancreatic islet cells 
as a source of antigen. 
The  TCR  specificities  of the  SS-  and  SS +  pools were 
compared by ELISA using different soluble TCR immobi- 
hzed  on  the  plates.  Both  SS-  and  SS +  antlsera  bound  to 
BDC  2.5 TCR-IgG1  and D10 TCR-IgG1  (TCR Vow-2/ 
V[3-8.2) proteins  (Fig. 7 A); the latter receptor was derived 
from the hen  egg conalbumin-specific and  I-Ak-restricted 
D10 T  cell clone (26). The cross-reaction appeared to be due 
to antibodies specific for epitopes of the o~- and [3-chains of 
the TCR  rather than the IgG1 constant region domains of 
the  chimeric  protein  because  the  antisera  recognized  the 
D10 dcTCR, and the D10 TCR individual cx- and ]3-chains 
(Fig.  7  A).  These  D10  TCR  proteins  were  produced  in 
soluble  form by deletion  of the  transmembrane  and  cyto- 
plasmic  portions  of the  TCR  without  the  addition  of the 
CH2 and CH3 domains oflgG1. In each, the carboxyl ter- 
minus was formed by the amino acid immediately follow- 
ing the cysteine residue that participates in interchain disul- 
fide bond formation. Both the SS + and SS-  antisera failed 
to  recognize  the  D10  single-chain  (sc) TCR  containing 
only the Vot and V[3 segments joined by a synthetic linker 
of 27  amino  acids  (Fig.  7  A).  That  the  variable  region  of 
the DI0 scTCR was intact was demonstrated by the ELISA 
data  showing  the  presence  of the  conformational,  clono- 
typic epitope recognized by the 3D3 mAb (Fig. 7 A). Both 
the  V[3-8  and  Vow-2 family-specific  epitopes  were  also 
present  (data not shown).  The absence of reactivity of the 
SS + and SS- antisera with the D10 scTCR therefore sug- 
gests  that  the  cross-reactivity with  the  D10  dcTCR,  and 
the  o~-chain  and  [3-chain  proteins  was  due  to  antibodies 
specific for the TCR  Cc~ and C[3 domains. 
The question arose as to why the SS + antiserum was ap- 
parently specific for TCR  clonotypic epitopes detected by 
indirect  immunofluorescent  staining  of the  BDC  2.5  cell 
surface and yet broadly cross-reactive against different solu- 
ble TCR by the ELISA. There were two possible explana- 
tions. Either the constant region epitopes recognized in the 
soluble TCR  were unavailable for antibody binding in the 
cell membrane-bound native BDC 2.5 TCR,  or the solu- 
ble TCR expressed unique Col and C13 deterrmnants formed 
by posttranslational  modification,  e.g.,  glycosylation,  spe- 
cific  to  the  baculovirus-infected  insect  cell.  To  address 
these  possibilities,  TCR  were immunoprecipitated  by the 
anti-C[3  mAb,  H57,  from  NP-40  detergent  extracts  of 
BDC 2.5  (TCR Vow-l/V[3-4), BDC 6.9  (TCR Vot-13.l/ 
V[3-4), B10 (TCR Vo~-11/V[3-16), and D10 (TCR VoL-2/ 
V[3-8.2) T  cell clones, and analyzed by 10.5% SDS-PAGE 
under  nonreducing  conditions.  Immunoblots  were  then 
performed with the same SS + and SS- antiserum pools pre- 
viously analyzed by the ELISA. The reactivity of both anti- 
sera with material of ~90  kD (Fig. 7 B), regardless of the 
T  cell source, indicated the presence of antibodies  specific 
for linear,  constant  region  epitopes  of the  T  cell-synthe- 
sized TCR.  Control mAb recognizing constant regions of 
TCR or- (H28) and [3- (501-1.1) chains reacted with mate- 
rial  of identical  size for each TCR.  In addition,  both the 
SS + and SS- antisera have been shown to immunoprecipi- 
tate  TCR  released  by NP-40  detergent  extraction  of the 
BDC 2.5, BDC 6.9,  D10 and B10 T  cell clones  (data not 
shown), indicating that denaturation of the TCR  in SDS is 
not required  for exposure  of the  constant  region  epitopes 
recognized by the antisera. 
Maternal Immunization  with BDC 2.5 TCR-IgG1  Protects 
Young NOD  Offspring  from  Diabetes Induced by the Adoptive 
Transfer of the BDC 2.5 T Cell Clone.  One  group  of 8-10- 
wk-old female NOD  mice was immunized with BDC 2.5 
TCR-IgG1 protein.  A  second group was similarly immu- 
nized with the D10 TCR-IgG1 protein,  and a third group 
was not immunized.  All the mice were mated with 8-10- 
wk-old male NOD  mice.  In the immunized groups, mat- 
ing began  on  the  day of the  first  boosting injection,  and 
pregnant mice were further boosted by the intravenous in- 
jection  of 20  p,g TCR-IgG1  between  days  13  and  16  of 
1762  Maternal Immunization with Soluble TCR m NOD Mice A 
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Figure 7.  NOD  mice ammu- 
nIzed with the BDC  2.5 TCP.- 
IgG1  protein  produce  antibod- 
ies  specific  for  constant  region 
epltopes exposed in soluble forms 
of the  TCR..  (A)  The  wells  of 
96-well plates  were coated with 
the indicated recombinant, solu- 
ble TCR preparations:  BDC 2 5 
TCR-IgG1,  D10  TCP.-IgG1, 
D10 dcTCR., D10 [3-chain, D10 
~x-chain, and D10 scTCP.,  After 
incubation with the sera or anU- 
bodies indicated on the ordinate, 
antibody  binding  to  the  plated 
TCR  was  detected  by  alkaline 
phosphatase-coupled  antibodies 
specific for mouse Ig K and k light chains. TCR ~x-chaln (H28)- and [3-chain (H57) -specific mAb, and the 3D3 mAb were blotxnylated, and their bind- 
Ing was detected with alkahne phosphatase-coupled streptavadm. The ELISA show that NOD mouse antl-BDC 2.5 TCR-IgG1 SS- and SS + antasera re- 
acted with epatopes shared by BDC 2.5 TCR-IgG1, D10 TCR-IgG1, D10 dcTCR and the D10 TCR 0~- and [3-chains, but not with DI0 scTCR that 
lacked the TCR constant-regaons. (/3) Equivalent numbers of cells from each of the four T cell clones (BDC 6.9, B10, BDC 2 5, and D10) were lysed 
In NP-40, and the TCR were lmmunoprecipatated with anta-TCR CIJ-speclfiC mAb H57 as described  In Materials and Methods. Protein was separated 
by SDS-PAGE under nonreduclng conditions and lmmunoblotted with the indicated serum (1:200 ddution).  H28 mAb was used at 4 ~g/ml, and 501 1.1 
mAb was used as a hybndoma supernatant  Antibody reactivity was detected with either polyspeclfiC goat anti-mouse Ig Ab conjugated to HILP or goat 
anti-hamster IgG-HlkP at a 1:2,000  dilution as descrabed In Matenals and Methods. 
gestation.  Nursing  mothers  were  given  final  boosts  14  d 
later.  Sera were  collected 4  d  after the final boost, and indi- 
rect immunofluorescent  cell surface staining (described ear- 
lier  in  Results)  was  used  to  determine  which  BDC  2.5 
TCP.-IgGl-immunized  mothers had mounted  a  BDC  2.5 
clonotype-specific  response.  All  of  the  D10  TCR.-IgG1 
immunized  mothers  made  antibodies  specific  for  the  cell 
surIhce clonotype  of the D10  TClk  as indicated by immu- 
nofluorescent staining of D10  cells but not B1  clone T  cells 
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(also  using TCR  V[~-8  segment)  or  AKP.  mouse  splenic 
T  cells.  The  serological specificity of the immune  response 
to soluble D10  TClq. will be described in detail elsewhere. 
At  10-21  d  of age,  pups  born  of the  immunized  NOD 
mothers  and  a  group  of nonimmunized  mothers  were  in- 
jected  (i.p.)  once  per week  for 3  wk  with  5  X  106-10  × 
106 viable T  cells of either the BDC  2.5  or BDC  6.9  islet- 
specific  clones.  The  onset  of diabetes  was  monitored,  and 
the data are presented in Table  1.  As expected from previ- Table  1.  Effect  of BDC 2.5 TCR-IgG1 Immunization  of Female NOD Mice on the Incidence of  Adoptively  Transferred Diabetes in 
Their Qffspring 
Soluble TCR 
inmmnization of  Maternal antibodies 
NOD mother  produced 
Incidence of diabetes in offspring 
injected with the diabetogenic T cell done 
BDC 2.5  BCD 6.9 
Nonlmmunlzed 
BDC 2.5 TC1K-IgG1 
BDC 2.5 TC1K-IgG1 
None 
BDC 2.5 clonotype-specific 
TCR constant region-specific-- 
non-T cell surface reacnve 
D10 TCR-IgG1  D10 clonotype-speclfiC  6/28 (21%)  Not tested 
20/63 (32%)  7/16 (44%) 
0/21  (0%)  4/10 (40%) 
17/29 (59%)  8/18 (44%) 
Female NOD mice were pnmed with TCR.-IgG1 proteins in CFA and boosted without adjuvant 14-21 d later. On the day of boosting the mice 
were mated with male NOD mice. Pregnant mace were further boosted by intravenous of  TCR.-IgG 1 between days 13 and 16 of  gestation. Nursing 
mothers were gaven final boosts 14 d later. Nommmunized mine received no TCtL-IgG1 injections. Antibody specificity was determined by redirect 
lmmunofluorescence (as described above) with mothers' sera 4 d after the final boost. In BDC 2.5 TCP,-IgG1 lmmumzed mice that failed to make a 
BDC 2.5 clonotype-speclfic response, the production of antibo&es to the TCR constant region was demonstrated by the EL1SA described above. At 
10-21 d of  age the offspring  were injected once per week for 3 wk with 5 ×  106-1 ×  10  v BDC 2.5 or BDC 6.9 T cells. Diabetes was monitored and 
&agnosed as descr,  bed m Materials and Methods. 
ously published data (19), both BDC 2.5 and BDC 6.9 T  cells 
induced  the  early onset  of diabetes.  Disease  occurred be- 
tween  10 and 25 d after the first injection of cells in 30-50% 
of pups  delivered  by nonimmunized  mothers,  as  opposed 
to the natural time of onset, which is usually at  >3 mo of 
age in unmanipulated NOD  mice. Immunizations of moth- 
ers that successfully resulted in a BDC 2.5 TCR. clonotype- 
specific antibody response  appeared  to  completely protect 
their pups from the  induction  of diabetes  by the  adoptive 
transfer of the BDC 2.5 T  cell clone. In contrast, injection 
of the BDC  6.9  clone into pups from mothers producing 
BDC  2.5  TCIK  clonotype-specific  antibodies  resulted  in 
accelerated  diabetes  with  an  incidence  similar  to  that  in 
control  pups  from  nonimmunized  mothers.  As  described 
above,  the islet-specific BDC  6.9 T  cell clone is  clonoty- 
picaily  distinct  from  BDC  2.5;  therefore  the  protection 
against  adoptively transferred  disease  afforded by matemal 
immunization appeared to be immunologically specific.  The 
immunological specificity of the maternally transferred pro- 
tection was further demonstrated by the failure of immuni- 
zation  against  the  D10  clonotype  to  provide  protection 
(Table  1).  The  BDC  2.5  TCIK  clonotype  specificity of 
the maternally transferred protection  strongly suggests that 
it was mediated via the transfer of specific antibodies from 
the mother, either transplacentally or in milk, or by both 
routes.  This  interpretation  was  supported  by the  demon- 
stration  that  3-4-wk-old offspring of mothers  successfully 
immunized  with  TCR-IgG1  protein  contained  titers  of 
clonotype-specific antibodies between  1  / 100 and >  1  / 1000, 
as determined by indirect lmmunofluorescence. 
Discussion 
Infection  of insect  cells  with  recombinant  baculovlrus 
has enabled the production of soluble BDC 2.5 TCR-IgG1 
in the milligram amounts required for the immunization of 
mice. The recombinant protein was purified by CJJ-specific 
H57  mAb-lmmunoaflinity  chromatography.  SDS-PAGE  of 
purified  material  under nonreducing conditions revealed a 
major species with an apparent molecular mass of 110 kD, 
which  is  within  the  range  predicted  from  the  molecular 
sizes of the BDC TCR  ot-IgG1 and  [3-IgG1 chains,  and a 
larger species of"-,200 kD. Since reduction of purified pro- 
tein yielded a band migrating in the size range expected for 
the  separate  chimeric  chains  (50-55  kiD),  the  larger  non 
reduced  species  probably  resulted  from covalent  aggrega- 
tion  due  to  mispaired  disulfide  bonds.  Immunopreclpita- 
tion of approximately equal amounts of the purified protein 
with both the H57 mAb and the Cot-specific H28 mAb, as 
judged by SDS-PAGE, indicated that the H57-immunoaf- 
finity purification  yielded  material  that  was  mainly  com- 
posed  of ot/[3  heterodimers.  The  heterodimenc  nature  of 
the purified protein was also supported by equivalent reac- 
tivity with both mAb in a BIAcore experiment. Analysis of 
the  conformation  and  functional  activity  of  BDC  2.5 
TC1K-IgG1 was not possible due to the lack ofa BDC 2.5 
clonotype-specific mAb,  and  the  unknown  nature  of the 
peptide which, when complexed with I-Ag  7 MHC  class II 
molecule  of the  NOD  mouse,  forms  the  antigen  for  the 
BDC  2.5  T  cell clone.  We have,  however,  used a similar 
technique  to  produce  and  purify a  soluble  version  of the 
D10 TCR  in milligram amounts.  In BIAcore experiments 
this recombinant protein was shown to bind the 3D3 mAb, 
which recognizes a conformational D10 clonotypic epltope, 
the V~-8 reactive SEC 2 superantigen,  and the specific an- 
tigen complex of I-A  k and conalbumm peptide (Khandekar 
et al.,  manuscript  submitted  for publication).  Because  im- 
munization  of NOD  mice  with  the  purified  BDC  2.5 
TCR-IgG1 stimulated the production of antibodies recog- 
nizing  clonotypic  epitopes  of the  BDC  2.5  cell  surface 
1764  Maternal Inu'nunizatlon with Soluble TCP,. in NOD Mice TCR,  it  would  appear that  similarly to  the  soluble  D10 
TCR,  structural features of the variable regions of the na- 
tive TCR  are possessed by the BDC 2.5  TCP,-IgG1 pro- 
tein. 
BDC  2.5  TCR-IgG1  immunization  experiments  pro- 
vided evidence that when administered in a soluble form, a 
TCI<  can  be  immunogenic  in  mice  of the  strain  from 
which  it was  derived.  Immunization of NOD  mice with 
the NOD-derived BDC 2.5 TCR-IgG1 protein stimulated 
antibody  responses  against  both  constant-  and  variable- 
region epitopes of the TCR. The production of antibodies 
that both recognized clonotypic epitopes of the native cell- 
surface  TCP,  and  inhibited  antigen-specific  activation  of 
the BDC 2.5  T  cell clone suggested that BDC 2.5  TCR- 
IgG1 immunizations might block the induction of diabetes 
by the  adoptive  transfer of the  BDC  2.5  clone  in  vivo. 
Using the maternal transfer of BDC 2.5 TCR.-specific anti- 
bodies we have indeed been able to demonstrate that sol- 
uble TCR immunization can bring about the clonal regu- 
lation  of  T  cell  function  in  vivo.  There  was  a  strong 
correlation  between  the  production  of TCP,.  clonotype- 
specific  antibodies  in  BDC  2.5  TCP,-IgG1  immunized 
NOD mothers and the inhibition of diabetes induction by 
the BDC 2.5 T  cell clone in their offspring. 
NOD mice that were immunized with BDC 2.5 TCP,.- 
IgG1 consistently mounted antibody responses against TCP, 
constant region epitopes. The NOD mouse anti-BDC 2.5 
TCR-IgG1  antisera  recognized  antigens  on  baculovirus- 
produced soluble versions of the BDC 2.5  TCI<, the D10 
TCP,,  and  the  individual  o~-  and  [3-chains  of the  D10 
TCR. The antlsera did not react with these nonclonotypic 
antigens of TCR  expressed in situ on the surface of T  cell 
clones.  It can be  concluded  that  during  immunization  in 
vivo,  the  BDC  2.5  TCR-IgG1  protein  presented  TCP, 
constant region antigens to the immune system that are not 
normally exposed on the T  cell surface. Furthermore,  the 
reaction  of the  antisera with  the  constant  region  antigens 
could be detected by immunoblotting of BDC  2.5,  BDC 
6.9, D10, and B10 TCR immunoprecipitated from the re- 
spective T  cell clones, indicating that some of the antigens 
are linear  epitopes.  It is possible that  these  epitopes were 
exposed  and  lmmunogenic  in  the  recombinant  soluble 
BDC 2.5 TCR-IgG1 preparations due to errors in folding, 
or partial denaturation of the protein. However, the ability 
of the antisera to immunoprecipitate TCP, from noniomc 
detergent extracts of different T  cell clones suggests that na- 
tive TCR  constant region epitopes were recognized.  The 
epitopes appear to be hidden in the TCR. when it is present 
in situ as an integral membrane protein of the T  cell, prob- 
ably due to their close proximity to either the cell-surface 
membrane, or components of the CD3  complex. Because 
they are normally unavailable for immune recognition, the 
constant region antigens presumably escape B cell tolerance 
during development of the immune system in vivo. 
In addition  to antibodies  to the  cryptic constant region 
epitopes, 56% of BDC  2.5  TC1K-IgG1 immunized NOD 
mice produced  antibodies  that  strongly  stained  the  BDC 
2.5 cell surface by indirect immunofluorescence. The anti- 
1765  McKeever et al. 
sera did not stain either the BDC 6.9 T  cell clone or NOD 
mouse splenic T  cells,  and whereas they blocked the anti- 
gen-specific activation of BDC 2.5  cells  in vitro, they did 
not interfere with the  activation of BDC  6.9  cells  by the 
same antigen. Among the BDC 2.5  TCR  epitopes recog- 
nized  by the  antisera,  some  at least  appeared  to  be  close 
enough  to  the  V[3  segment  to  allow  the  antibodies  to 
block,  albeit to  a relatively small extent,  the binding  of a 
V13-4 family-specific mAb to the BDC 2.5 cell-surface re- 
ceptor. The antisera did not contain antibodies recognizing 
V13-4  family-specific epitopes, because they did  not  stain 
BDC 6.9 cells which also use the V13-4 gene segment. The 
data suggest that the  antisera recognized BDC  2.5  clono- 
typic determinants. 
The  serologic  specificities  of the  antibody  response  in 
NOD  mice  immunized  with  the  syngeneic  BDC  2.5 
TCR-IgG1 do not seem to be unique because we have ob- 
served  very  similar  responses  in  AKR  mice  immunized 
with  soluble  D10  TCP,  (lesson,  M.I.,  U.  McKeever,  S. 
Khandekar, J. Newcomb, J. Naylor, P. Gregory, P. Brauer, B. 
Bettencourt, J. Banerji,  and B. Jones, manuscript in prepara- 
tion). The effect of the IgG1 portion on the immunogenic- 
ity of the  chimeric receptor has not been formally evalu- 
ated in the  NOD  mouse.  Preliminary data in AKR  mice 
indicated that soluble D10 dcTC1k produced in the bacu- 
lovirus system without the IgG1 domams could also stimu- 
late antibody responses. The responses were of similar po- 
tency  and  specificity  to  those  mounted  against  the  D10 
TC1K-IgG1  protein,  and  therefore  the  Fc  portion  of the 
TCR-IgG1 protein does not appear to increase the immu- 
nogenicity of the TCIK appreciably. 
The  success  of  soluble  TCR-IgG1  immunization  in 
stimulating the production of antibodies recognizing native 
clonotypic  epitopes of the  BDC  2.5  TCR. led  us  to  per- 
form  an  experiment  designed  to  investigate  the  concept 
that TC1K immunization in vivo can bring about the clonal 
regulation  of autoimmune T  cells.  As explained in the in- 
troducnon to this article, we had to adopt a strategy of ma- 
ternal immunization in order to provide TCR-specific se- 
rum  antibodies  in  the  young  (2-3-wk-old)  NOD  mice 
used as recipients of the diabetogenic T  cells.  The data in- 
dicate that when BDC 2.5  TCR-IgG1 immunization suc- 
cessfully stimulated a BDC 2.5 clonotype-specific antibody 
response in the  NOD  mothers, then the litters were pro- 
tected from the mduction of diabetes by the BDC 2.5 T  cell 
clone.  Protection  appeared to be T  cell clone specific be- 
cause maternal immunization against the BDC  2.5  clono- 
type did not prevent the transfer of diabetes by the BDC 
6.9  T  cell  clone.  Imnmnological specificity was also  sup- 
ported  by the  failure  of D10  TC1K-IgG1  immunizations 
that  stimulated  a  D10  TC1K  clonotype-specific  antibody 
response  in  the  NOD  mothers  to  protect  the  offspring 
against diabetes induced by the BDC 2.5  T  cell clone.  As 
expected,  BDC  2.5  TC1K-IgG1  immunizations  that  only 
stimulated  a  response  to  non-cell-surface  TC1L  constant 
region epitopes failed to afford protection in the litters. 
The data  demonstrate that using a relatively simple ex- 
pression and purification strategy, it is possible to produce a soluble  TCR-IgG1  protein  in  which  the  TCR.  portion 
possesses  clonotypic  determinants  that  are  immunogenic 
and cross-reactive with those found in the functionally ac- 
tive cell-surface form of the TCR.. The ability ofsyngeneic 
immunizations with BDC 2.5 TCR.-IgG1 to induce a hu- 
moral response that appeared to inhibit T  cell-induced dis- 
ease  m  a  clone-specific fashion  supports  the  concept that 
TCR.  vaccinations  that  stimulate  humoral  immunity  can 
potentially modulate  the  course  of a  T  cell mediated au- 
toimmune  disease.  The  challenge  now is  to  design TCR 
vaccination strategies that can alter the course of spontane- 
ous autoimmune disease.  Although in the outbred human 
population it seems unlikely that autoimmune diseases will 
be generally triggered by T  cell clones that share a clono- 
typic epitope, multiple sclerosis  may prove to be an excep- 
tion.  Oksenberg and colleagues  (48)  have found common 
amino acid sequence  motifs in  the  VDJ region  of T  cells 
using  the  V~-5.2/3  gene  segment  in  multiple  sclerosis 
brain  plaques.  These VDJ  sequences  might  represent im- 
munogenic  clonotypic epitopes that could be targeted by 
TCR  vaccination.  Recent  experiments  in  an  adoptive 
transfer model of mouse EAE with the  encephalitogemc 
T  cell clone L10C1  indicate  that suppression of a single 
T  cell clone can prevent disease (49). L10Cl recognizes the 
MBP  epitope  p87-99,  and  the  CDII.3  sequences  in  the 
TCR. ix- and [3-chains are homologous to those in rat clones 
specific  for  MBP  p87-99  and  human  multiple  sclerosis 
brain plaques.  After injection  of L10C1  cells into  (PL/J  × 
SJL/J)F1  mice, treatment of the mice with an altered pep- 
tide ligand prevented EAE.  The heterogeneous expression 
of TCR  genes  observed in the inflammatory infiltrates  of 
EAE induced by L10C1 in untreated mice was dramatically 
reduced by administration of the altered peptide ligand af- 
ter the onset of paralysis.  Our data demonstrating the effi- 
cacy of TCR. vaccination in the adoptive transfer model of 
mouse insnlin-dependent diabetes mellitus suggest that vac- 
cination against the CDR3 epitope(s) shared by L10C1 and 
human brain plaque  sequences  could prevent disease  in  a 
similar  fashion.  Treatment  with  anti-TCR  antibodies  of 
appropriate specificity should also be effective, and in  the 
human this would be a clinically acceptable approach. 
While vaccination against TCI< clonotypes will probably 
not be applicable to  all  autoimmune  diseases,  vaccination 
against particular TCR. V-regions might be more feasible. 
Although  the  topic  of TCP, V-gene usage in  autoimmu- 
nity is controversial (50), there are data to suggest that some 
human autoimmune diseases  involve T  cells that use a re- 
stricted repertoire  of TCt< V-region segments, for exam- 
ple, TCR. V~-3,  6,  14,  15,  and  17 in rheumatoid arthritis 
(51-54),  and  TCR. VI3-3 and  13.1  in  the  skin  lesions  of 
psoriasis  (55).  The  progression  of such  diseases  might  be 
ameliorated by soluble TCP,. immunizations that stimulate 
an antibody response against the family specific epitopes of 
the particular V[3 segments involved. Indeed, as mentioned 
in  the  introduction  to  this  article,  immunization  against 
peptides  derived  from  the  TCR  V[3-8.2  segment  could 
sometimes prevent EAE in those strains  of rat and mouse in 
which  the  encephalltogenic  T  cells  use  the  V[3-8.2  gene 
predominantly.  TCR  peptide  vaccination seems to prime 
T  cells that regulate encephalitogenic T  cell function via an 
ill-defined  mechanism  (7).  In contrast,  the  mechanism of 
TCR.-specific antibody-mediated immunoregulation is com- 
paratively straightforward, and we have now designed strat- 
egies where soluble TCR. immunizations can stimulate an 
antibody response that ohgoclonally modulates T  cells  us- 
mg  V~-genes  belonging  to  a  particular  family.  Mouse 
strains of the VI3" haplotype have a genomic deletion of the 
V~  5,  V[3 8,  VI3 9,  V~  11,  V~  12,  and V[3  13  gene loci 
(56).  Vaccination of these strains with a soluble TCR con- 
taming one of the missing V~ segments should induce the 
formation of antibodies  against its family-specific epitopes 
(57).  We are currently investigating the immunoregulatory 
activity of maternal immunization against a TCR V~-fam- 
ily in F1  offspring that inherit a functional complement of 
V~-gene segments from a father of a nondeleted strain. 
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